Laser ablation‐inductively coupled plasma‐mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma

Abstract

AbstractAimsPleural mesothelioma (PM) is a highly aggressive thoracic tumour with poor prognosis. Although reduced tissue drug accumulation is one of the key features of platinum (Pt) resistance, little is known about Pt distribution in human PM.MethodsWe assessed Pt levels of blood samples and surgically resected specimens from 25 PM patients who had received neoadjuvant Pt‐based chemotherapy (CHT). Pt levels and tissue distributions were measured by laser ablation‐inductively coupled plasma‐mass spectrometry and correlated with clinicopathological features.ResultsIn surgically resected PM specimens, mean Pt levels of nontumourous (fibrotic) areas were significantly higher (vs tumourous regions, P = 0.0031). No major heterogeneity of Pt distribution was seen within the tumourous areas. Pt levels correlated neither with the microvessel area nor with apoptosis rate in the tumourous or nontumourous regions. A significant positive correlation was found between serum and both full tissue section and tumourous area mean Pt levels (r = 0.532, P = 0.006, 95% confidence interval [95% CI] 0.161‐0.771 and r = 0.415, P = 0.039, 95% CI 0.011‐0.702, respectively). Furthermore, a significant negative correlation was detected between serum Pt concentrations and elapsed time from the last cycle of CHT (r = −0.474, P = 0.017, 95% CI −0.738‐−0.084). Serum Pt levels correlated negatively with overall survival (OS) (P = 0.029).ConclusionsThere are major differences in drug distribution between tumourous and nontumourous areas of PM specimens. Serum Pt levels significantly correlate with full section and tumourous area average Pt levels, elapsed time from the last CHT cycle, and OS. Further studies investigating clinicopathological factors that modulate tissue Pt concentration and distribution are warranted.